2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3769 Prevalence of acquired complex (chromoanagenesis-like) chromosomal rearrangements involving DYRK1A and/or ASXL1 in blast phase - myeloproliferative neoplasm

Joseph Tripodi, PhD, Colin Butler2, Brandon Veremis, DDS3, Daiva Ahire, MS4, John O. Mascarenhas, MD5, Ronald Hoffman, MD6, Vesna Najfeld, PhD7
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Background: Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal disorders driven primarily by JAK2, CALR, or MPL acquired somatic mutations. A subset of patients (pts) progress to accelerated or blast-phase disease (MPN-AP/BP). The genomic drivers of this progression remain poorly understood. Chromoanagenesis (CAG), a collective term encompassing chromothripsis, chromoanasynthesis, and chromoplexy, refers to complex chromosomal rearrangements leading to multiple gains, losses, and amplifications involving one or a few chromosomes. These events occur in 7% of acute myeloid leukemias (Fontana et al., Leukemia 2018) and have recently been identified in 17% of cases with MPN-BP (Brierley et al., Nat Genet 2025). The aim of this study was to determine whether CAG occurs across the broader spectrum of chronic MPNs, and how these events relate to concurrent molecular alterations.

Methods: We retrospectively reviewed 670 pts with Ph-MPN (ET n=176, PV n=122, prefibrotic PMF n=36, PMF n=225, MPN-NOS n=70, MPN-AP/BP n=41) who underwent chromosomal microarray analysis (CMA) between November 2017 and June 2026. Concurrent conventional cytogenetics, FISH, and myeloid malignancy gene mutational data obtained using extended NGS panels were evaluated. Cases with complex rearrangements consistent with CAG (multiple localized gains, losses, and amplifications) were identified and characterized.

 Results: Eleven of 670 pts (1.6%) harbored complex rearrangements consistent with CAG. At the time of CMA testing, 8 of 11 patients (73%) had MPN blast phase (MPN-BP), while the remaining three had PV (n=1), PMF (n=1), or MPN-NOS (n=1). The cohort included 8 males and 3 females with a median age of 71 years (range, 58–82). CMA identified 77 genomic abnormalities (median, 3 per patient; range, 1–38), comprising 35 gains (45%), 32 losses (42%), and 10 copy-neutral loss of heterozygosity (CN-LOH) events (13%).

 CAG most frequently involved chromosomes 20 (n=5) and 21 (n=4), followed by chromosomes 7 (n=2) and 13 (n=2); additional chromosomes included 1, 9, 10, 12, 15, 16, and 17. Among the 5 patients with chromosome 20 CAG (MPN-BP, n=2; PV, n=1; PMF, n=1; MPN-NOS, n=1), 4 harbored partial 20q deletions encompassing ASXL1, while one patient exhibited both ASXL1 deletion and mutation of the remaining allele (VAF 54%), consistent with biallelic inactivation. This patient also had concurrent chromosome 21 CAG. All five patients with chromosome 20 CAG were JAK2 V617F+ and carried additional mutations including DNMT3A, TET2, TP53, and U2AF1.

 Chromosome 21 was the second most frequently involved chromosome, with a minimal overlapping amplified region containing DYRK1A, a gene recently implicated in chromothripsis-associated genomic instability (Brierley et al. Nat Genet. 2025). Notably, all four patients with chromosome 21 CAG harbored TP53 alterations (monoallelic or biallelic), together with recurrent mutations in JAK2 V617F (3/4), EZH2, SF3B1, ASXL1, DNMT3A, U2AF1, and HRAS.

 Overall, 10 of 11 patients (91%) were JAK2 V617F+ while TP53 mutations were identified in 8 of 11 (73%), including 7 with biallelic TP53 inactivation resulting from mutation with CN-LOH 17p (n=3), mutation with 17p deletion (n=1), or two independent TP53 mutations (n=3). Additional recurrent mutations included DNMT3A (n=3), U2AF1 (n=2), and TET2 (n=2), whereas ASXL1, EZH2, SF3B1, SETBP1, ZRSR2, and HRAS were each identified in individual patients. Three patients (27%) harbored one or more high-risk mutation (range, 1–2).

Conclusion: Acquired chromoanagenesis-like events are rare but recurrent across the spectrum of MPNs and are markedly enriched in MPN-BP, supporting a role in leukemic progression. These rearrangements frequently co-occurred with biallelic TP53 loss of function alterations and recurrently involved chromosomes 20 and 21. Our findings confirm the previously reported frequency and association between TP53 alterations and DYRK1A amplification in pts with MPN-BP (Brierley et al., Nat Genet. 2025) and newly identify recurrent 20q deletions involving ASXL1. CAG-like events were also detected in chronic-phase MPNs (3/11; 27%), suggesting that these alterations may precede overt BP in a subset of patients. The relative contributions of TP53 loss of function events and CAG involving ASXL1 or DYRK1A to the development of MPN-BP remain the subject of continued investigation.

Joseph Tripodi, PhD: No relevant conflicts of interest to declare.